Genmab | GEN - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.72B 134M 2026-06
argenx SE USD 417M 62M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bayer EUR 3.7B 356M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Demant DKK 6.09B 135M 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Fresenius Medical Care EUR 749M 36M 2026-03
Genmab DKK 208M 60M 2025-12
GlaxoSmithKline GBP 2.19B 75M 2026-06
GN Store Nord DKK 763M 688M 2026-03
GRIFOLS EUR 289M 8M 2026-06
Hikma Pharmaceutical USD 288M 149M 2025-12
Insmed USD 247.26M 34.78M 2026-03
Lakefront Biotherapeutics EUR 35.5M 8.91M 2026-03
Merck EUR 1.52B 80M 2026-03
Novartis USD 3.24B 101M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
UCB EUR 1.47B 193M 2025-12